long-term effects of semaglutide Comparative safety and side and tirzepatide: Implications for clinical decision-making in obesity management Best GLP-1 for Weight Loss:

Huang CC, Chou CA, Chen WY, et al

"Semaglutide (Wegovy) Criteria for Coverage." kaiserpermanente.org (PDF) Novo Nordisk

Discontinue Ozempic at least two months before planned pregnancy, and inform surgical teams of use to allow appropriate perioperative planning

A Pivotal Contribution from Regulatory Agencies To Relevant Clinical Observations The requirements to assess the safety of new diabetes medications, including GLP-1R agonists, set forth by The United States Food and Drug Administration (FDA) were specified in the December 2008 guidance document titled Guidance for Industry: Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. A draft of this document had been issued in March 2008 and the final document followed recommendations from the Endocrinologic and Metabolic Drugs Advisory Committee that convened on July 1 and 2, 2008 [25]